Utilizing our in-depth understanding of the bio-medical landscape, we look for answers, for efficacy, for impact as we explore innovative healthcare technologies and potential investment opportunities.
AUM: $11.8B · Form ADV, 13 Jul 2026
| i | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasdaq: PRAX | Current | Pharmaceutical Preparations | COM NEW | 2,024,781 | -11,205 | -0.6% | 7.24% | $590M | -$92M | 10.27% | $8.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: AMLX | Current | Pharmaceutical Preparations | COM | 10,573,735 | +2,238,853 | +26.9% | 8.22% | $308M | +$158M | 5.36% | $3.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Spyre Therapeutics, Inc. | Nasdaq: SYRE | Current | Pharmaceutical Preparations | COM NEW | 3,280,943 | -1,038,553 | -24.0% | 3.45% | $292M | -$91M | 5.09% | $9.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: MRNA | Current | Biological Products, (No Diagnostic Substances) | COM | +285.0% | $270M | +$200M | 4.70% | $80.7B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: CELC | Current | Services-Medical Laboratories | COM | 3,179,794 | -17,406 | -0.5% | 6.47% | $265M | -$85M | 4.61% | $2.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: RYTM | Current | Pharmaceutical Preparations | COM | 2,532,556 | -53,739 | -2.1% | 3.65% | $241M | -$46M | 4.20% | $8.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ROIV | Current | Pharmaceutical Preparations | SHS | 6,510,961 | -1,574,500 | -19.5% | 0.90% | $238M | -$48M | 4.15% | $28.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: RLAY | Current | Biological Products, (No Diagnostic Substances) | COM | 12,730,336 | -1,375,851 | -9.8% | 5.76% | $230M | -$34M | 4.00% | $3.5B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ASND | Current | Pharmaceutical Preparations | ORD SHS | 971,521 | -192,200 | -16.5% | $221M | -$89M | 3.86% | $16.8B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: TVTX | Current | Pharmaceutical Preparations | COM | 3,542,913 | -209,661 | -5.6% | 3.69% | $209M | -$5M | 3.63% | $4.6B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: FRNM | Current | Services-Medical Laboratories | COMMON STOCK | 12,606,053 | +12,606,053 | New | 11.31% | $199M | +$199M | 3.46% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: EWTX | Current | Pharmaceutical Preparations | COM | 4,138,282 | -235,692 | -5.4% | 3.78% | $168M | -$10M | 2.93% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Inhibrx Biosciences, Inc. | Nasdaq: INBX | Current | Biological Products, (No Diagnostic Substances) | COM | 1,292,463 | -5,300 | -0.4% | 8.75% | $129M | +$6M | 2.25% | $1.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: NRIX | Current | Pharmaceutical Preparations | COM | 5,371,629 | +1,051,207 | +24.3% | 4.92% | $127M | +$23M | 2.22% | $1.5B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Kardigan, Inc. | Nasdaq: KARD | Current | Pharmaceutical Preparations | COM | 8,200,662 | 0 | 0.0% | 8.76% | $121M | -$75M | 2.11% | $1.2B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Meiragtx Hldgs PLC | Current | COM | 10,786,658 | 0 | 0.0% | $119M | -$27M | 2.07% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: PTGX | Current | Pharmaceutical Preparations | COM | 836,579 | -145,300 | -14.8% | 1.28% | $118M | -$2M | 2.05% | $8.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IMTX | Current | Biological Products, (No Diagnostic Substances) | SHS | 11,246,516 | +863,060 | +8.3% | $99M | -$6M | 1.72% | $906M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: ZYME | Current | Pharmaceutical Preparations | COM | 3,545,501 | -637,452 | -15.2% | 5.14% | $94M | -$15M | 1.64% | $1.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: RVMD | Current | Biological Products, (No Diagnostic Substances) | COM | 683,100 | -94,500 | -12.2% | 0.32% | $92M | -$9M | 1.60% | $34.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ORKA | Current | Pharmaceutical Preparations | COM | 1,072,363 | -272,700 | -20.3% | 1.58% | $89M | -$39M | 1.56% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: SLDB | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 11,906,646 | 0 | 0.0% | 10.67% | $86M | -$33M | 1.50% | $719M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BCRX | Current | Biological Products, (No Diagnostic Substances) | COM | 10,301,888 | -7,000 | -0.1% | 4.00% | $86M | -$17M | 1.49% | $1.9B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Avalyn Pharma Inc. | Nasdaq: AVLN | Current | Pharmaceutical Preparations | COM SHS | 2,675,296 | 0 | 0.0% | 6.03% | $76M | -$12M | 1.33% | $1.3B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: SLS | Current | Pharmaceutical Preparations | COM NEW | +205.8% | $68M | +$46M | 1.18% | $3.0B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: TNGX | Current | Pharmaceutical Preparations | COM | 2,693,000 | -684,000 | -20.3% | 1.59% | $67M | -$38M | 1.17% | $3.8B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: WAT | Current | Laboratory Analytical Instruments | COM | 135,000 | +135,000 | New | 0.14% | $59M | +$59M | 1.03% | $86.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: RGEN | Current | Biological Products, (No Diagnostic Substances) | COM | 272,456 | +24,244 | +9.8% | 0.43% | $52M | +$19M | 0.91% | $10.9B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: AORT | Current | Surgical & Medical Instruments & Apparatus | COM | 2,112,290 | +375,000 | +21.6% | 4.33% | $48M | +$9M | 0.84% | $904M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: ANRO | Current | Pharmaceutical Preparations | COM SHS | 1,760,950 | +151,057 | +9.4% | 4.39% | $45M | +$2M | 0.78% | $1.1B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Opus Genetics, Inc. | Nasdaq: IRD | Current | Pharmaceutical Preparations | COM | 9,000,000 | +9,000,000 | New | 9.31% | $44M | +$44M | 0.76% | $394M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: LKFT | Current | Pharmaceutical Preparations | SPON ADR | 1,242,404 | +1,242,404 | New | $37M | +$37M | 0.64% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| NYSE: ABT | Current | Pharmaceutical Preparations | COM | 345,225 | +345,225 | New | 0.02% | $34M | +$34M | 0.59% | $180B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| BlossomHill Therapeutics, Inc. | Nasdaq: BLSM | Current | Pharmaceutical Preparations | COM | 1,812,193 | +1,812,193 | New | 5.70% | $34M | +$34M | 0.59% | $458M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Spdr Series Trust | Current | Fund | ST STR SP BIOT | -33.6% | $32M | -$16M | 0.55% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |||||
| Orchestra BioMed Holdings, Inc. | Nasdaq: OBIO | Current | Surgical & Medical Instruments & Apparatus | COM | 5,037,606 | -300 | -0.0% | 6.40% | $31M | +$10M | 0.55% | $551M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: CRVS | Current | Pharmaceutical Preparations | COM | 2,510,441 | -157,000 | -5.9% | 2.98% | $29M | -$11M | 0.50% | $844M | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Anteris Technologies Global Corp. | Nasdaq: AVR | Current | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM | 3,425,476 | 0 | 0.0% | 3.51% | $27M | -$7M | 0.46% | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Adlai Nortye Group Ltd. | Nasdaq: ANL | Current | Pharmaceutical Preparations | SPONSORED ADS | 1,660,502 | -132,688 | -7.4% | $27M | +$6M | 0.46% | $583M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| MiniMed Group, Inc. | Nasdaq: MMED | Current | Surgical & Medical Instruments & Apparatus | COM | 1,320,000 | +1,320,000 | New | 0.47% | $26M | +$26M | 0.45% | $4.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: CTMX | Current | Pharmaceutical Preparations | COM | 9,268,061 | -1,171,124 | -11.2% | 4.25% | $25M | -$14M | 0.44% | $447M | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Rapport Therapeutics, Inc. | Nasdaq: RAPP | Current | Pharmaceutical Preparations | COM | 724,342 | -49,000 | -6.3% | 1.22% | $24M | -$8M | 0.42% | $1.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: SEPN | Current | Pharmaceutical Preparations | COM | 567,479 | +567,479 | New | 1.19% | $22M | +$22M | 0.39% | $1.9B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| X4 Pharmaceuticals, Inc | Nasdaq: XFOR | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 7,350,491 | -583,000 | -7.3% | 7.20% | $21M | -$16M | 0.37% | $302M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: ELVN | Current | Pharmaceutical Preparations | COM | 462,506 | +462,506 | New | 0.63% | $21M | +$21M | 0.37% | $3.4B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| SAB Biotherapeutics, Inc. | Nasdaq: SABS | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 6,627,501 | 0 | 0.0% | 7.36% | $21M | -$5M | 0.37% | $262M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: DYN | Current | Pharmaceutical Preparations | COM | 1,265,362 | -1,423,873 | -52.9% | 0.68% | $20M | -$39M | 0.36% | $3.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: EOLS | Current | Pharmaceutical Preparations | COM | 2,459,285 | 0 | 0.0% | 3.72% | $20M | +$3M | 0.34% | $463M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Yarrow Bioscience, Inc. | Nasdaq: YARW | Current | Pharmaceutical Preparations | COM | 813,098 | +813,098 | New | 5.34% | $18M | +$18M | 0.32% | $217M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: IMVT | Current | Biological Products, (No Diagnostic Substances) | COM | 519,345 | -838,038 | -61.7% | 0.25% | $18M | -$35M | 0.31% | $6.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SCTX | Current | Biological Products, (No Diagnostic Substances) | COM | 920,341 | +920,341 | New | 4.86% | $17M | +$17M | 0.30% | $250M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nautilus Biotechnology, Inc. | Nasdaq: NAUT | Current | Laboratory Analytical Instruments | COM | 11,564,744 | -69,467 | -0.6% | 9.08% | $16M | -$5M | 0.29% | $276M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: STRO | Current | Biological Products, (No Diagnostic Substances) | COM SHS | 970,846 | -334,000 | -25.6% | 5.85% | $16M | -$28M | 0.27% | $145M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Newamsterdam Pharma Company | Current | ORDINARY SHARES | -13.9% | $15M | -$2M | 0.25% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||||||
| Surrozen, Inc./DE | Nasdaq: SRZN | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 439,685 | -230,966 | -34.4% | 2.31% | $14M | +$1M | 0.25% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| EyePoint, Inc. | Nasdaq: EYPT | Current | Laboratory Analytical Instruments | COM NEW | -51.7% | $14M | -$15M | 0.24% | $30M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |||
| Nasdaq: GRAL | Current | Services-Medical Laboratories | COM | 96,911 | +96,911 | New | 0.22% | $14M | +$14M | 0.24% | $4.5B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: DBVT | Current | Biological Products, (No Diagnostic Substances) | SPONSORED ADS | 1,136,534 | -516,816 | -31.3% | 0.36% | $13M | -$14M | 0.23% | $592M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: DHR | Current | Industrial Instruments For Measurement, Display, and Control | COM | 60,000 | -70,000 | -53.8% | 0.01% | $13M | -$11M | 0.23% | $155B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IRTC | Current | Surgical & Medical Instruments & Apparatus | COM | 113,766 | -110,000 | -49.2% | 0.34% | $13M | -$14M | 0.23% | $3.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: GH | Current | Services-Medical Laboratories | COM | 70,000 | +28,673 | +69.4% | 0.05% | $12M | +$6M | 0.22% | $19.7B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IVVD | Current | Biological Products, (No Diagnostic Substances) | COM | 13,762,637 | -4,727,999 | -25.6% | 4.66% | $12M | -$4M | 0.21% | $132M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ADPT | Current | Biological Products, (No Diagnostic Substances) | COM | 412,325 | -805,000 | -66.1% | 0.25% | $12M | -$14M | 0.21% | $4.5B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Veradermics, Inc | NYSE: MANE | Current | Pharmaceutical Preparations | COMMON STOCK | 97,000 | +97,000 | New | 0.23% | $12M | +$12M | 0.20% | $5.2B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: AXGN | Current | Electromedical & Electrotherapeutic Apparatus | COM | 280,000 | +32,688 | +13.2% | 0.47% | $12M | +$0.3M | 0.20% | $3.4B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| PALISADE BIO, INC. | Nasdaq: PALI | Current | Biological Products, (No Diagnostic Substances) | COM | 8,425,065 | 0 | 0.0% | 4.70% | $11M | -$6M | 0.20% | $166M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: CBIO | Current | Pharmaceutical Preparations | COM | 706,942 | +500,000 | +241.6% | 1.82% | $10M | +$7M | 0.18% | $539M | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BBNX | Current | Surgical & Medical Instruments & Apparatus | COM | 538,159 | -294,785 | -35.4% | 0.99% | $10M | -$3M | 0.18% | $724M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Seaport Therapeutics, Inc. | Nasdaq: SPTX | Current | Pharmaceutical Preparations | COMMON STOCK | 500,000 | 0 | 0.0% | 0.93% | $10M | -$0.8M | 0.18% | $981M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Entera Bio Ltd. | Nasdaq: ENTX | Current | Biological Products, (No Diagnostic Substances) | SHS | 3,431,372 | +3,431,372 | New | 1.97% | $10M | +$10M | 0.17% | $571M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: MIRM | Current | Pharmaceutical Preparations | COM | 115,391 | 0 | 0.0% | 0.18% | $10M | -$4M | 0.17% | $6.2B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Uniqure NV | Current | SHS | 402,773 | +234,773 | +139.7% | $10M | +$2M | 0.17% | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | ||||
| Xeris Biopharma Holdings, Inc. | Nasdaq: XERS | Current | Pharmaceutical Preparations | COM | 933,671 | +466,658 | +99.9% | 0.51% | $9M | +$5M | 0.16% | $3.0B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Research Alliance Corp IV | Nasdaq: RACD | Current | Blank Checks | CL A ORD SHS | 700,000 | +700,000 | New | $8M | +$8M | 0.14% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: CAPR | Current | Pharmaceutical Preparations | COM NEW | 850,000 | -77.7% | 1.46% | $8M | -$28M | 0.14% | $438M | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Viridian Therapeutics, Inc.\DE | Nasdaq: VRDN | Current | Pharmaceutical Preparations | COM | 381,452 | -200,528 | -34.5% | 0.34% | $8M | -$3M | 0.14% | $3.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: ABVX | Current | Pharmaceutical Preparations | SPONSORED ADS | 74,000 | 0 | 0.0% | $7M | -$3M | 0.13% | $7.1B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | ||
| enGene Therapeutics Inc. | Nasdaq: ENGN | Current | Biological Products, (No Diagnostic Substances) | COM | 3,482,169 | -1,340,000 | -27.8% | 5.20% | $7M | -$1M | 0.12% | $118M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: BLLN | Current | Services-Medical Laboratories | CL A | 65,209 | -21,603 | -24.9% | $7M | -$3M | 0.12% | $4.3B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | ||
| AgomAb Therapeutics NV | Nasdaq: AGMB | Current | Biological Products, (No Diagnostic Substances) | SPONSORED ADS | 600,000 | 0 | 0.0% | $7M | -$1M | 0.12% | $277M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| LeonaBio, Inc. | Nasdaq: LONA | Current | Biological Products, (No Diagnostic Substances) | COM | 1,859,322 | 0 | 0.0% | 14.22% | $7M | -$10M | 0.12% | $32M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: BIIB | Current | Biological Products, (No Diagnostic Substances) | COM | 28,030 | -248,143 | -89.9% | 0.02% | $6M | -$53M | 0.11% | $36.5B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ADRX | Current | Pharmaceutical Preparations | COM | 300,000 | +300,000 | New | 0.27% | $6M | +$6M | 0.10% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nuvectis Pharma, Inc. | Nasdaq: NVCT | Current | Pharmaceutical Preparations | COM | 240,000 | -760,000 | -76.0% | 0.70% | $5M | -$13M | 0.09% | $682M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: OLMA | Current | Pharmaceutical Preparations | COM | 575,000 | +575,000 | New | 0.66% | $5M | +$5M | 0.09% | $626M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Oculis Holding AG | Nasdaq: OCS | Current | Pharmaceutical Preparations | ORDINARY SHARES | 440,827 | -368,000 | -45.5% | $4M | -$7M | 0.07% | $415M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: UNH | Current | Hospital & Medical Service Plans | COM | 10,000 | -106,806 | -91.4% | <0.01% | $4M | -$45M | 0.06% | $296B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Mobia Medical, Inc. | Nasdaq: MOBI | Current | Surgical & Medical Instruments & Apparatus | COMMON STOCK | 343,654 | -180,000 | -34.4% | 1.03% | $3M | -$4M | 0.06% | $395M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| NYSE: BHVN | Current | Pharmaceutical Preparations | COM | New | $3M | +$3M | 0.05% | $2.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Outset Medical, Inc. | Nasdaq: OM | Current | Electromedical & Electrotherapeutic Apparatus | COM NEW | 833,333 | 0 | 0.0% | 4.42% | $2M | -$1M | 0.04% | $55M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: CBLL | Current | Electromedical & Electrotherapeutic Apparatus | COM | 98,779 | +98,779 | New | 0.25% | $2M | +$2M | 0.04% | $1.0B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Edesa Biotech, Inc. | Nasdaq: EDSA | Current | Pharmaceutical Preparations | COM NEW | 563,239 | 0 | 0.0% | 5.84% | $2M | -$2M | 0.04% | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Braveheart Bio, Inc. | Nasdaq: BRVE | Current | Pharmaceutical Preparations | COM SHS | 115,000 | +115,000 | New | 0.13% | $2M | +$2M | 0.04% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Outlook Therapeutics, Inc. | Nasdaq: OTLK | Current | Biological Products, (No Diagnostic Substances) | COM | 3,139,216 | 0 | 0.0% | 1.29% | $2M | -$3M | 0.03% | $98M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Adagio Med Hldgs Inc | Current | COM | 9,876,586 | 0 | 0.0% | $2M | -$5M | 0.03% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: ADMA | Current | Biological Products, (No Diagnostic Substances) | COM | 113,765 | 0 | 0.0% | 0.05% | $1M | +$0.2M | 0.02% | $3.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| KIORA PHARMACEUTICALS INC | Nasdaq: KPRX | Current | Pharmaceutical Preparations | COM | 438,471 | 0 | 0.0% | 9.91% | $1M | -$0.0M | 0.02% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Medline Inc. | Nasdaq: MDLN | Current | Surgical & Medical Instruments & Apparatus | COM CL A | 28,000 | 0 | 0.0% | $1.0M | -$0.1M | 0.02% | $49.8B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: XGN | Current | Services-Medical Laboratories | COM | 114,893 | 0 | 0.0% | 0.45% | $0.9M | +$0.4M | 0.02% | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Ascendis Pharma A/S Sponsored ADR | Exited | SPONSORED ADR | 0 | -1,531,421 | -100.0% | -$350M | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | ||||||
| Centessa Pharmaceuticals PLC | Exited | SPONSORED ADS | 0 | -5,258,903 | -100.0% | -$209M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Nuvalent Inc | Exited | COM | 0 | -1,580,505 | -100.0% | -$195M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||||
| Apogee Therapeutics Inc | Exited | COM | 0 | -1,308,113 | -100.0% | -$174M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||||
| Merus N V | Exited | COM | 0 | -1,353,093 | -100.0% | -$127M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Exact Sciences Corp | Exited | COM | 0 | -1,200,487 | -100.0% | -$122M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Intra-Cellular Therapies Inc | Exited | COM | 0 | -786,358 | -100.0% | -$104M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: INSM | Exited | Pharmaceutical Preparations | COM PAR $.01 | 0 | -702,130 | -100.0% | -$101M | $31.7B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Arcellx | Exited | COMMON STOCK | 0 | -1,466,071 | -100.0% | -$96M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Exited | COM | 0 | -6,370,851 | -100.0% | -$91M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | |||||||
| Astria Therapeutics Inc | Exited | COM | 0 | -6,485,420 | -100.0% | -$85M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Verona Pharma PLC | Exited | SPONSORED ADS | 0 | -524,088 | -100.0% | -$56M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Akero Therapeutics Inc | Exited | COM | 0 | -1,135,766 | -100.0% | -$54M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: IONS | Exited | Pharmaceutical Preparations | COM | 0 | -566,000 | -100.0% | -$45M | $4.5B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: IOVA | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -12,711,788 | -100.0% | -$42M | $3.4B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: JAZZ | Exited | Pharmaceutical Preparations | SHS USD | 0 | -170,000 | -100.0% | -$41M | $15.2B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: SION | Exited | Pharmaceutical Preparations | COM | 0 | -905,000 | -100.0% | -$40M | $134M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Engene Holdings Inc | Exited | COM | 0 | -5,827,506 | -100.0% | -$40M | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | ||||||
| Day One Biopharmaceuticals Inc | Exited | COM | 0 | -1,755,799 | -100.0% | -$38M | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | ||||||
| Cidara Therapeutics, Inc. | Exited | COM NEW | 0 | -165,131 | -100.0% | -$36M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Soleno Therapeutics Inc | Exited | COM | 0 | -430,439 | -100.0% | -$36M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: IRON | Exited | Pharmaceutical Preparations | COM | 0 | -450,743 | -100.0% | -$36M | $3.5B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: ARGX | Exited | Biological Products, (No Diagnostic Substances) | SPONSORED ADR | 0 | -59,510 | -100.0% | -$35M | $59.2B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: CORT | Exited | Pharmaceutical Preparations | COM | 0 | -398,385 | -100.0% | -$35M | $7.1B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| NYSE: PEN | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -110,529 | -100.0% | -$34M | $12.6B | Q1 2026 | 15 May 2026 | Q4 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: DMRA | Exited | Pharmaceutical Preparations | COM NEW | 0 | -1,223,000 | -100.0% | -$32M | $1.5B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| NYSE: CRL | Exited | Services-Commercial Physical & Biological Research | COM | 0 | -140,000 | -100.0% | -$32M | $15.7B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: CAI | Exited | Services-Medical Laboratories | COM | 0 | -1,136,206 | -100.0% | -$31M | $5.3B | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: AXSM | Exited | Pharmaceutical Preparations | COM | 0 | -118,450 | -100.0% | -$29M | $7.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| RAPT Therapeutics | Exited | COM NEW | 0 | -825,890 | -100.0% | -$28M | Q1 2026 | 15 May 2026 | Q4 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| PALVELLA THERAPEUTICS, INC. | Nasdaq: PVLA | Exited | Pharmaceutical Preparations | COM | 0 | -266,287 | -100.0% | -$28M | $2.1B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | |||
| Nasdaq: DRUG | Exited | Pharmaceutical Preparations | COM NEW | 0 | -377,544 | -100.0% | -$28M | $204M | Q2 2026 | 14 Aug 2026 | Q4 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: PCVX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -706,567 | -100.0% | -$27M | $9.2B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| TENAX THERAPEUTICS, INC. | Nasdaq: TENX | Exited | Pharmaceutical Preparations | COM NEW | 0 | -1,700,000 | -100.0% | -$25M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: BLTE | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -151,979 | -100.0% | -$24M | $6.1B | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: KOD | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -848,900 | -100.0% | -$24M | $6.4B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: PRCT | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -290,659 | -100.0% | -$23M | $1.5B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Instil Bio, Inc. | Nasdaq: TIL | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | 0 | -345,545 | -100.0% | -$23M | $38M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Nasdaq: LIVN | Exited | Electromedical & Electrotherapeutic Apparatus | SHS | 0 | -429,000 | -100.0% | -$23M | $5.1B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Springworks Therapeutics Inc | Exited | COM | 0 | -692,263 | -100.0% | -$22M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| NYSE: MDT | Exited | Electromedical & Electrotherapeutic Apparatus | SHS | 0 | -245,332 | -100.0% | -$22M | $129B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Aldeyra Therapeutics, Inc. | Nasdaq: ALDX | Exited | Pharmaceutical Preparations | COM | 0 | -4,185,632 | -100.0% | -$22M | $44M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | |||
| Nasdaq: ISRG | Exited | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM NEW | 0 | -51,884 | -100.0% | -$21M | $138B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: CTNM | Exited | Pharmaceutical Preparations | CL A | 0 | -1,255,592 | -100.0% | -$21M | $355M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: PODD | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -60,387 | -100.0% | -$19M | $9.5B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| NYSE: CVS | Exited | Retail-Drug Stores and Proprietary Stores | COM | 0 | -220,000 | -100.0% | -$17M | $102B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: OMDA | Exited | Services-Health Services | COM | 0 | -786,330 | -100.0% | -$17M | $775M | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| NYSE: GKOS | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -140,000 | -100.0% | -$16M | $14.1B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: MDGL | Exited | Pharmaceutical Preparations | COM | 0 | -46,500 | -100.0% | -$15M | $9.2B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: DXCM | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -225,758 | -100.0% | -$15M | $29.9B | Q1 2026 | 15 May 2026 | Q1 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: SVRA | Exited | Pharmaceutical Preparations | COM | 0 | -2,400,000 | -100.0% | -$14M | $1.1B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: ARVN | Exited | Pharmaceutical Preparations | COM | 0 | -740,749 | -100.0% | -$14M | $441M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: ICLR | Exited | Services-Commercial Physical & Biological Research | SHS | 0 | -44,353 | -100.0% | -$13M | $14.3B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: ARQT | Exited | Pharmaceutical Preparations | COM | 0 | -1,358,500 | -100.0% | -$13M | $3.4B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: CGON | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -419,450 | -100.0% | -$12M | $7.3B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: TYRA | Exited | Pharmaceutical Preparations | COM | 0 | -511,226 | -100.0% | -$12M | $1.4B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| NYSE: OSCR | Exited | Hospital & Medical Service Plans | CL A | 0 | -400,000 | -100.0% | -$11M | $8.1B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Acrivon Therapeutics, Inc. | Nasdaq: ACRV | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -5,360,858 | -100.0% | -$11M | $60M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| NYSE: EW | Exited | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM | 0 | -145,000 | -100.0% | -$11M | $59.7B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| NYSE: BSX | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -250,000 | -100.0% | -$11M | $62.3B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: XNCR | Exited | Pharmaceutical Preparations | COM | 0 | -527,671 | -100.0% | -$11M | $2.6B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: TARS | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -186,662 | -100.0% | -$10M | $3.8B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Evommune, Inc. | NYSE: EVMN | Exited | Pharmaceutical Preparations | COM SHS | 0 | -448,350 | -100.0% | -$10M | $299M | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | |||
| Nasdaq: NMRA | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -5,104,097 | -100.0% | -$10M | $65M | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | ||||
| Cargo Therapeutics Inc | Exited | COM | 0 | -2,431,085 | -100.0% | -$10M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: RARE | Exited | Pharmaceutical Preparations | COM | 0 | -270,000 | -100.0% | -$10M | $1.8B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| ArriVent BioPharma, Inc. | Nasdaq: AVBP | Exited | Pharmaceutical Preparations | COM | 0 | -415,000 | -100.0% | -$10M | $582M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Gossamer Bio Inc | Exited | COM | 0 | -3,139,669 | -100.0% | -$10M | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| MapLight Therapeutics, Inc. | Nasdaq: MPLT | Exited | Pharmaceutical Preparations | COM | 0 | -550,000 | -100.0% | -$10M | $357M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | |||
| Crinetics Pharmaceuticals Inc | Exited | COM | 0 | -184,525 | -100.0% | -$9M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: NTRA | Exited | Services-Medical Laboratories | COM | 0 | -34,689 | -100.0% | -$9M | $42.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Inari Med Inc | Exited | COM | 0 | -178,797 | -100.0% | -$9M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: XENE | Exited | Pharmaceutical Preparations | COM | 0 | -200,791 | -100.0% | -$9M | $3.7B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: NBIX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -65,050 | -100.0% | -$9M | $15.8B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Research Alliance Corp III | Nasdaq: RACC | Exited | Pharmaceutical Preparations | ORD SHS CL A | 0 | -750,000 | -100.0% | -$8M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: CGEM | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -426,478 | -100.0% | -$8M | $589M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Allogene Therapeutics, Inc. | Nasdaq: ALLO | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -2,725,000 | -100.0% | -$8M | $231M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Kestra Medical Technologies Ltd. | Exited | SHS | 0 | -285,000 | -100.0% | -$8M | Q1 2026 | 15 May 2026 | Q1 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: JANX | Exited | Pharmaceutical Preparations | COM | 0 | -292,686 | -100.0% | -$7M | $630M | Q4 2025 | 17 Feb 2026 | Q4 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Tempus AI, Inc. | Nasdaq: TEM | Exited | Services-Computer Programming, Data Processing, Etc. | CL A | 0 | -85,000 | -100.0% | -$7M | $10.9B | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | |||
| Nasdaq: ZBIO | Exited | Pharmaceutical Preparations | COM | 0 | -744,035 | -100.0% | -$6M | $1.7B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: DCTH | Exited | Surgical & Medical Instruments & Apparatus | COM NEW | 0 | -462,422 | -100.0% | -$6M | $669M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: PHAT | Exited | Pharmaceutical Preparations | COM | 0 | -532,000 | -100.0% | -$6M | $413M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: KYMR | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -69,935 | -100.0% | -$5M | $10.2B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: PEPG | Exited | Pharmaceutical Preparations | COM | 0 | -829,870 | -100.0% | -$5M | $370M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| FILANA THERAPEUTICS, INC. | Nasdaq: FLNA | Exited | Pharmaceutical Preparations | COM | -100.0% | -$5M | $28M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||||
| NYSE: GMED | Exited | Surgical & Medical Instruments & Apparatus | CL A | 0 | -88,500 | -100.0% | -$5M | $9.1B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Tectonic Therapeutic, Inc. | Nasdaq: TECX | Exited | Biological Products, (No Diagnostic Substances) | COM | -100.0% | -$5M | $411M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | |||||
| Nasdaq: HTFL | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -150,000 | -100.0% | -$5M | $3.9B | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: AQST | Exited | Pharmaceutical Preparations | COM | 0 | -747,193 | -100.0% | -$5M | $466M | Q1 2026 | 15 May 2026 | Q1 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: COGT | Exited | Pharmaceutical Preparations | COM | 0 | -121,082 | -100.0% | -$5M | $4.8B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| OnKure Therapeutics, Inc. | Nasdaq: OKUR | Exited | Pharmaceutical Preparations | COM CL A | 0 | -1,004,439 | -100.0% | -$4M | $114M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Nasdaq: KRYS | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -17,500 | -100.0% | -$4M | $9.4B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| OCULAR THERAPEUTIX, INC | Nasdaq: OCUL | Exited | Pharmaceutical Preparations | COM | -100.0% | -$4M | $1.3B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | |||||
| Helix Acquisition Corp Ii | Exited | CL A ORD SHS | 0 | -398,000 | -100.0% | -$4M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| VERU INC. | Nasdaq: VERU | Exited | Pharmaceutical Preparations | COM | 0 | -6,483,157 | -100.0% | -$4M | $36M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Nasdaq: AVTX | Exited | Pharmaceutical Preparations | COM NEW | 0 | -219,813 | -100.0% | -$4M | $390M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Inhibikase Therapeutics, Inc. | Nasdaq: IKT | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | 0 | -2,315,000 | -100.0% | -$4M | $182M | Q2 2026 | 14 Aug 2026 | Q4 2024 | Q1 2026 | 13F, Q1 2026 | |||
| Nasdaq: DTIL | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | 0 | -426,293 | -100.0% | -$4M | $264M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Perspective Therapeutics, Inc. | NYSE: CATX | Exited | Pharmaceutical Preparations | COM NEW | 0 | -1,190,263 | -100.0% | -$4M | $95M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Nasdaq: TWST | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -36,812 | -100.0% | -$4M | $7.6B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Lineage Cell Therapeutics, Inc. | NYSE: LCTX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -7,236,843 | -100.0% | -$4M | $207M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Nasdaq: SDGR | Exited | Pharmaceutical Preparations | COM | 0 | -202,400 | -100.0% | -$4M | $2.0B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Scpharmaceuticals Inc | Exited | COM | 0 | -583,142 | -100.0% | -$3M | Q4 2025 | 17 Feb 2026 | Q4 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Apellis Pharmaceuticals Inc | Exited | COM | 0 | -80,956 | -100.0% | -$3M | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | ||||||
| ImmunityBio, Inc. | Nasdaq: IBRX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -1,221,734 | -100.0% | -$3M | $7.0B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Nasdaq: VKTX | Exited | Pharmaceutical Preparations | COM | 0 | -105,597 | -100.0% | -$3M | $3.3B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: BCYC | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -197,108 | -100.0% | -$3M | $214M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: ABSI | Exited | Services-Commercial Physical & Biological Research | COM | 0 | -700,000 | -100.0% | -$3M | $1.4B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Pyxis Oncology, Inc. | Nasdaq: PYXS | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -1,178,307 | -100.0% | -$3M | $201M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| BIODESIX INC | Nasdaq: BDSX | Exited | Services-Medical Laboratories | COM | 0 | -108,694 | -100.0% | -$2M | $92M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | |||
| Verrica Pharmaceuticals Inc. | Nasdaq: VRCA | Exited | Pharmaceutical Preparations | COM | 0 | -3,249,669 | -100.0% | -$2M | $50M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Nasdaq: SPRY | Exited | Pharmaceutical Preparations | COM | -100.0% | -$2M | $338M | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: MREO | Exited | Pharmaceutical Preparations | SPON ADS | 0 | -876,961 | -100.0% | -$2M | $44M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| TRINITY BIOTECH PLC | Nasdaq: TRIB | Exited | In Vitro & In Vivo Diagnostic Substances | SPONS ADR NEW | 0 | -1,790,000 | -100.0% | -$2M | $4M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| enVVeno Medical Corp | Nasdaq: NVNO | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -1,759,035 | -100.0% | -$2M | $4M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| Nasdaq: GPCR | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -34,852 | -100.0% | -$2M | $1.2B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Lyra Therapeutics Inc | LYRA | Exited | COM NEW | 0 | -229,382 | -100.0% | -$1M | $0.1M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: FATE | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -345,575 | -100.0% | -$1M | $123M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: FULC | Exited | Pharmaceutical Preparations | COM | 0 | -238,000 | -100.0% | -$1M | $283M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| PALATIN TECHNOLOGIES INC | Nasdaq: PTN | Exited | Pharmaceutical Preparations | COM NEW | 0 | -61,945 | -100.0% | -$1M | $9M | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | |||
| Traws Pharma, Inc. | Nasdaq: TRAW | Exited | Pharmaceutical Preparations | COM NEW | 0 | -421,781 | -100.0% | -$1.0M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: RCKT | Exited | Pharmaceutical Preparations | COM | 0 | -140,726 | -100.0% | -$0.9M | $236M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Lexeo Therapeutics, Inc. | Nasdaq: LXEO | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -139,835 | -100.0% | -$0.9M | $244M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| Forte Biosciences Inc. | Exited | COM NEW | 0 | -68,192 | -100.0% | -$0.9M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: NVAX | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | -100.0% | -$0.8M | $1.3B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Singular Genomics Systems In | Exited | COM NEW | 0 | -50,896 | -100.0% | -$0.8M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Kyverna Therapeutics, Inc. | Nasdaq: KYTX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -150,000 | -100.0% | -$0.7M | $276M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| CUMBERLAND PHARMACEUTICALS INC | Nasdaq: CPIX | Exited | Pharmaceutical Preparations | COM | 0 | -196,978 | -100.0% | -$0.6M | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Applied Therapeutics Inc | Exited | COM | 0 | -860,000 | -100.0% | -$0.4M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nanobiotix S.A. | Nasdaq: NBTX | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -105,053 | -100.0% | -$0.4M | $1.4B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Apyx Medical Corp | Nasdaq: APYX | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -150,000 | -100.0% | -$0.3M | $101M | Q4 2025 | 17 Feb 2026 | Q4 2024 | Q3 2025 | 13F, Q3 2025 | |||
| Nasdaq: KALA | Exited | Pharmaceutical Preparations | COM NEW | 0 | -55,227 | -100.0% | -$0.3M | $2M | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 |